This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Shandong Xuanzhu Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd.. Active years: 2025.
Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2025
Title: Haibo Wang - Innovator in Pharmaceutical Chemistry
Introduction
Haibo Wang is a notable inventor based in Jinan, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for cancer treatment. His work has led to the creation of a unique crystal form of a polycyclic anaplastic lymphoma kinase inhibitor.
Latest Patents
Haibo Wang holds 1 patent for his invention titled "Crystal form of polycyclic anaplastic lymphoma kinase inhibitor." This patent relates to a specific crystal form of a compound, 5-chloro-N-(2-(isopropylsulfonyl)phenyl)-N-(7-methyl-8-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)pyrimidine-2,4-diamine. The invention includes a preparation method, a pharmaceutical composition comprising the crystal form, and its use in treating anaplastic lymphoma kinase-mediated cancers and other related diseases.
Career Highlights
Throughout his career, Haibo Wang has worked with prominent companies in the pharmaceutical industry. He has been associated with Shandong Xuanzhu Pharma Co., Ltd. and Xuanzhu Biopharmaceutical Co., Ltd. His expertise in drug development has been instrumental in advancing therapeutic options for patients.
Collaborations
Haibo Wang has collaborated with various professionals in his field, including Guohui Han, who is a key coworker in his research endeavors.
Conclusion
Haibo Wang's innovative work in pharmaceutical chemistry, particularly his patent for a polycyclic anaplastic lymphoma kinase inhibitor, showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against cancer and related diseases.